Arrowhead Pharmaceuticals (ARWR) Prepaid Assets (2010 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Prepaid Assets came in at $21.7 million in Q1 2026, down 8.62% YoY from $23.8 million in Q1 2025, and up 35.31% on a QoQ basis from $16.1 million in Q4 2025.
Analysis
Arrowhead Pharmaceuticals (ARWR) Prepaid Assets (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 17 years of Prepaid Assets data on file, last reported at $21.7 million in Q1 2026.
- Quarterly Prepaid Assets fell 8.62% year-over-year to $21.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.7 million (down 8.62% YoY) and the FY2025 annual result came in at $13.5 million, up 171.79% from the prior year.
- Prepaid Assets grew to $21.7 million in Q1 2026, from $16.1 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $23.8 million in Q1 2025 to a low of $4.0 million in Q3 2023.
- A 5-year average of $11.9 million and a median of $10.1 million in 2023 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2022 — Prepaid Assets soared 363.18% — and 2023, when it slumped 80.04%.
- Tracing ARWR's Prepaid Assets over 5 years: stood at $8.4 million in 2022, then declined by 15.55% to $7.1 million in 2023, then jumped by 31.84% to $9.4 million in 2024, then jumped by 71.4% to $16.1 million in 2025, then soared by 35.31% to $21.7 million in 2026.
- The last three Prepaid Assets figures came in at $21.7 million (Q1 2026), $16.1 million (Q4 2025), and $13.5 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.40 Bn | 10.80 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 35.52 Mn |
| Mar 31, 2026 | 21.72 Mn |
| Dec 31, 2025 | 22.86 Mn |
| Sep 30, 2025 | 13.52 Mn |
| Jun 30, 2025 | 23.69 Mn |
| Mar 31, 2025 | 23.77 Mn |
| Dec 31, 2024 | 9.37 Mn |
| Sep 30, 2024 | 9.54 Mn |
| Jun 30, 2024 | 9.21 Mn |
| Mar 31, 2024 | 11.02 Mn |
| Dec 31, 2023 | 10.52 Mn |
| Sep 30, 2023 | 8.81 Mn |
| Jun 30, 2023 | 10.05 Mn |
| Mar 31, 2023 | 14.44 Mn |
| Dec 31, 2022 | 25.19 Mn |
| Sep 30, 2022 | 20.20 Mn |
| Jun 30, 2022 | 8.89 Mn |
| Mar 31, 2022 | 7.80 Mn |
| Dec 31, 2021 | 5.20 Mn |
| Sep 30, 2021 | 4.36 Mn |